Pub Date : 2018-03-05DOI: 10.4172/2324-9110.1000210
M. Arslan, B. Gulek, A. P. Kelle, Serkan Akbulut, E. Uğurlu, I. B. Guney, Sinan Sozutok, O. Kulahci
Purpose: The purpose of this study was to investigate if PET-CT and CT were able to exclude N2 and N3 disease in patients with breast cancer. Materials and Methods: In this study, the PET-CT reports of 211 patients who had been previously diagnosed with breast cancer and who had undergone PET-CT examinations and sentinel lymph node biopsies or axillary lymph node dissections, were reevaluated retrospectively. Whether PET-CT and CT were able to exclude N2 or N3 disease was the subject of evaluation of this study. Results: It was found at the end of the study that PET-CT was able to exclude N2 and N3 involvement in 92,9 % of the cases, whereas CT alone could do the same exclusion in 93,6 %. Conclusion: PET-CT and CT can well exclude N2 and N3 disease in patients with breast cancer. It may be suggested that PET-CT can replace sentinel lymph node biopsy in future preoperative evaluations.
{"title":"Can FDG PET/CT and CT Exclude N2 and N3 Nodal Disease in Patients with Breast Cancer?","authors":"M. Arslan, B. Gulek, A. P. Kelle, Serkan Akbulut, E. Uğurlu, I. B. Guney, Sinan Sozutok, O. Kulahci","doi":"10.4172/2324-9110.1000210","DOIUrl":"https://doi.org/10.4172/2324-9110.1000210","url":null,"abstract":"Purpose: The purpose of this study was to investigate if PET-CT and CT were able to exclude N2 and N3 disease in patients with breast cancer. \u0000Materials and Methods: In this study, the PET-CT reports of 211 patients who had been previously diagnosed with breast cancer and who had undergone PET-CT examinations and sentinel lymph node biopsies or axillary lymph node dissections, were reevaluated retrospectively. Whether PET-CT and CT were able to exclude N2 or N3 disease was the subject of evaluation of this study. \u0000Results: It was found at the end of the study that PET-CT was able to exclude N2 and N3 involvement in 92,9 % of the cases, whereas CT alone could do the same exclusion in 93,6 %. \u0000Conclusion: PET-CT and CT can well exclude N2 and N3 disease in patients with breast cancer. It may be suggested that PET-CT can replace sentinel lymph node biopsy in future preoperative evaluations.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46933335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-02-15DOI: 10.4172/2324-9110.1000211
S. Al-Shibli, N. M. Amjad, Muna Khaleel Dheyab Al-Kubaisi, Norra Harun, Emad M. Nafie, S. Mizan
Introduction: Leptin, the hormone secreted from white adipose tissue is suspected of being a causative factor in tumorigenesis in various tissues. Thus it might be a link between obesity and breast cancer. Objectives: In this project we tried to study causative association of obesity and serum leptin with invasive ductal breast cancer (IDC) in a sample of Malaysian population. Methods: We measured various obesity parameters, and estimated serum leptin levels in a group of healthy control and IDC patients. After confirming diagnosis by standard histopathological methods, serum leptin levels were estimated using ELISA. Both the pre-and postoperative leptin levels were measured with the Patient group. Results: The difference between the serum leptin levels of the Control and the Patient group were highly significant with a P value of 0.05). Conclusion: Since high serum leptin in IDC patients persists unabated in the post-operative state, we infer that the source of leptin in these cases cannot be the breast cancer tissue itself and leptin cannot be a marker for breast cancer. Highly significant association between serum leptin and IDC patients suggests that leptin in serum might play a causative role in the tumorigenesis of breast cancer, and it might be an important connection between obesity and breast cancer. Therefore, leptin signal transduction pathway might be a prospective therapeutic target in the treatment and prevention of IDC.
{"title":"Serum Leptin Might Be Causally Correlated to Invasive Ductal Breast Carcinoma","authors":"S. Al-Shibli, N. M. Amjad, Muna Khaleel Dheyab Al-Kubaisi, Norra Harun, Emad M. Nafie, S. Mizan","doi":"10.4172/2324-9110.1000211","DOIUrl":"https://doi.org/10.4172/2324-9110.1000211","url":null,"abstract":"Introduction: Leptin, the hormone secreted from white adipose tissue is suspected of being a causative factor in tumorigenesis in various tissues. Thus it might be a link between obesity and breast cancer. \u0000Objectives: In this project we tried to study causative association of obesity and serum leptin with invasive ductal breast cancer (IDC) in a sample of Malaysian population. \u0000Methods: We measured various obesity parameters, and estimated serum leptin levels in a group of healthy control and IDC patients. After confirming diagnosis by standard histopathological methods, serum leptin levels were estimated using ELISA. Both the pre-and postoperative leptin levels were measured with the Patient group. \u0000Results: The difference between the serum leptin levels of the Control and the Patient group were highly significant with a P value of 0.05). \u0000Conclusion: Since high serum leptin in IDC patients persists unabated in the post-operative state, we infer that the source of leptin in these cases cannot be the breast cancer tissue itself and leptin cannot be a marker for breast cancer. Highly significant association between serum leptin and IDC patients suggests that leptin in serum might play a causative role in the tumorigenesis of breast cancer, and it might be an important connection between obesity and breast cancer. Therefore, leptin signal transduction pathway might be a prospective therapeutic target in the treatment and prevention of IDC.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46630756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-29DOI: 10.4172/2324-9110.1000E112
B. Lb
Our group has been pioneering in exploring that the pharmacological handling of Ca2+/cAMP signalling interaction could be a better therapeutic method for increasing neurotransmission in psychiatric disorders, and stimulating neuroprotection for combating neurodegenerative diseases, such as Alzheimer´s disease. Indeed, Ca2+ is a classic intracellular second messenger, now well recognized as a ubiquitous molecule that controls several processes, including gene transcription, cell cycle regulation, mobility, apoptosis, neurotransmitter release and muscle contraction. In addition, cAMP, another vital intracellular messenger, modulates since cardiac contraction to neurotransmitter release. Do these intracellular messengers ´work´ independently? Of course not, and we demonstrated it! Through groundbreaking experiments (including one by accident!), our group discovered that the paradoxical effects (e.g. reduction of intracellular Ca2+ concentration, and enhancing of neurotransmitter release?!) produced by L-type Ca2+ channel blockers (CCBs) resulted from interferences on the Ca2+/ cAMP signalling interaction. Considering the widely use of CCBs as antihypertensive drugs, and for combating arrhythmia, the elucidation of these paradoxical effects proved to be very important (specially for clinical reasons). How does this history correlate to cancer field? Considering the notion that Ca2+/cAMP signalling interaction is a fundamental cellular process, which exists in many cell types, whether this interaction may be a novel therapeutic target to alter cancer tumor growth, angiogenesis and metastasis, without affecting normal cell physiology deserves special consideration. Thus, this editorial article highlights the latest advances made by our group in the field of Ca2+/cAMP signalling interaction.
{"title":"Ca2+ and Camp: Do these Intracellular Messengers Work’Independently? Of Course Not, and the History Goes Ahead…","authors":"B. Lb","doi":"10.4172/2324-9110.1000E112","DOIUrl":"https://doi.org/10.4172/2324-9110.1000E112","url":null,"abstract":"Our group has been pioneering in exploring that the pharmacological handling of Ca2+/cAMP signalling interaction could be a better therapeutic method for increasing neurotransmission in psychiatric disorders, and stimulating neuroprotection for combating neurodegenerative diseases, such as Alzheimer´s disease. Indeed, Ca2+ is a classic intracellular second messenger, now well recognized as a ubiquitous molecule that controls several processes, including gene transcription, cell cycle regulation, mobility, apoptosis, neurotransmitter release and muscle contraction. In addition, cAMP, another vital intracellular messenger, modulates since cardiac contraction to neurotransmitter release. Do these intracellular messengers ´work´ independently? Of course not, and we demonstrated it! Through groundbreaking experiments (including one by accident!), our group discovered that the paradoxical effects (e.g. reduction of intracellular Ca2+ concentration, and enhancing of neurotransmitter release?!) produced by L-type Ca2+ channel blockers (CCBs) resulted from interferences on the Ca2+/ cAMP signalling interaction. Considering the widely use of CCBs as antihypertensive drugs, and for combating arrhythmia, the elucidation of these paradoxical effects proved to be very important (specially for clinical reasons). How does this history correlate to cancer field? Considering the notion that Ca2+/cAMP signalling interaction is a fundamental cellular process, which exists in many cell types, whether this interaction may be a novel therapeutic target to alter cancer tumor growth, angiogenesis and metastasis, without affecting normal cell physiology deserves special consideration. Thus, this editorial article highlights the latest advances made by our group in the field of Ca2+/cAMP signalling interaction.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46375649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-29DOI: 10.4172/2324-9110.1000212
S. Zergeroğlu, T. Güngör, H. Yalcin
Aim: Target in cervical cancer screenings is to use easy applying, cheap and diagnostic-assisted screening tests together. The most important thing is to do HPV-DNA analysis with Pap smear. The aim in this study is to perform a detailed follow-up program according to the results of patients who had been diagnosed with cervical intraepithelial lesion (SIL) who applied to the hospital for 2 years and to find out whether being used HPV-DNA results affected the SIL lesions without applying a smear test (pap test) in the menopausal patients with negative HPV-DNA analysis by performing only HPVDNA analysis. Materials and Methods: A smear test was requested for 11,850 patients aged 50 ± 3.2 in the Zekai Tahir Burak Women’s Health Training and Research Hospital between the years 2015-2016 for a 2-year period. 5180 patients are menopausal. HPV-DNA genotyping analyzes were performed for HPV 16,18,31,33,35,3 9,45,51,56,58,66 and 68 types while 1102 of these patients were followed by pap test for Low grade SIL, and colposcopies were performed and biopsies were taken by the same gynecologist. In this study, Chi-square test, Mann Whitney U test were used for the statistical analysis and Spearman Rho test was used for correlation analysis with IBM SPSS statistical program version 21.0. Values of p ≤ 0.001 were considered significant. Non-significant analyzes were not used in this study. In the result of histopathological examination, cases were compared with smear findings. For colposcopy, Barcelona 2002 colposcopy terminology was used. In the histopathologic analysis of colposcopic biopsies, Bethesda System 2014 version and also HPV ascia LAST in ano-genital lesion coexistence were used for classification. Findings: Patients were selected among 11,850 patients who applied to the hospital between 2015 and 2016 and were received cervical cytology specimens. 5180 patients were in menopausal period. 1102 of these patients have LSIL. 278 of the LSIL 1102 patients were reported as HPV (+) CIN I neoplasia and the remaining 824 patients as HPV (-) non-neoplastic lesion. CIN I lesion in 270 patients and CIN II lesion in 8 were determined with colposcopic biopsy performed in HPV-DNA (+) group (n=278). CIN I lesion in 670 patients and CIN II in 14 patients were also found with colposcopic biopsy performed in HPV-DNA (-) group (n=840); in 140 patients dysplasia was not observed. We think that only HPV-DNA analysis is not appropriate for menopausal HPV (+), pap smear negative patients with negative
目的:宫颈癌筛查的目标是使用方便、廉价和辅助诊断的筛查方法。最重要的是在子宫颈抹片检查中做HPV-DNA分析。本研究的目的是根据就诊2年的宫颈上皮内病变(SIL)患者的诊断结果进行详细的随访，并对绝经期HPV-DNA阴性的患者仅进行HPVDNA分析，在不进行涂片检查(巴氏试验)的情况下使用HPV-DNA结果是否影响SIL病变。材料与方法:对2015-2016年Zekai Tahir Burak妇女健康培训与研究医院(Zekai Tahir Burak Women’s Health Training and Research Hospital)年龄为50±3.2岁的11,850例患者进行了为期2年的涂片检查。5180例患者处于更年期。对HPV 16、18、31、33、35、3、9、45、51、56、58、66和68型进行HPV- dna基因分型分析，其中1102例患者接受巴氏涂片检查检查低级别SIL，并由同一妇科医生进行阴道镜检查和活检。本研究采用IBM SPSS统计程序21.0版进行统计分析，统计分析采用卡方检验、Mann Whitney U检验，相关性分析采用Spearman Rho检验。p≤0.001被认为是显著的。本研究未采用非显著性分析。在组织病理学检查的结果，病例与涂片结果比较。对于阴道镜检查，使用了2002年巴塞罗那的阴道镜检查术语。在阴道镜活检的组织病理学分析中，采用Bethesda系统2014版和HPV ascia LAST在肛门-生殖器病变共存中进行分类。结果:选取2015 - 2016年就诊的11850例宫颈细胞学标本患者。绝经期5180例。这些患者中有1102人患有LSIL。1102例LSIL患者中有278例报告为HPV (+) CIN肿瘤，其余824例为HPV(-)非肿瘤性病变。HPV-DNA(+)组(278例)经阴道镜活检确定CIN I病变270例，CIN II病变8例。HPV-DNA(-)组(n=840)经阴道镜活检发现CIN病变670例，CIN病变14例;140例患者未观察到发育不良。我们认为仅HPV- dna分析不适用于绝经期HPV(+)、巴氏涂片阴性的患者
{"title":"Should Post-Menopausal Women be Screened only with HPV Test in Cervical Cancers?","authors":"S. Zergeroğlu, T. Güngör, H. Yalcin","doi":"10.4172/2324-9110.1000212","DOIUrl":"https://doi.org/10.4172/2324-9110.1000212","url":null,"abstract":"Aim: Target in cervical cancer screenings is to use easy applying, cheap and diagnostic-assisted screening tests together. The most important thing is to do HPV-DNA analysis with Pap smear. The aim in this study is to perform a detailed follow-up program according to the results of patients who had been diagnosed with cervical intraepithelial lesion (SIL) who applied to the hospital for 2 years and to find out whether being used HPV-DNA results affected the SIL lesions without applying a smear test (pap test) in the menopausal patients with negative HPV-DNA analysis by performing only HPVDNA analysis. \u0000Materials and Methods: A smear test was requested for 11,850 patients aged 50 ± 3.2 in the Zekai Tahir Burak Women’s Health Training and Research Hospital between the years 2015-2016 for a 2-year period. 5180 patients are menopausal. HPV-DNA genotyping analyzes were performed for HPV 16,18,31,33,35,3 9,45,51,56,58,66 and 68 types while 1102 of these patients were followed by pap test for Low grade SIL, and colposcopies were performed and biopsies were taken by the same gynecologist. In this study, Chi-square test, Mann Whitney U test were used for the statistical analysis and Spearman Rho test was used for correlation analysis with IBM SPSS statistical program version 21.0. Values of p ≤ 0.001 were considered significant. Non-significant analyzes were not used in this study. \u0000In the result of histopathological examination, cases were compared with smear findings. For colposcopy, Barcelona 2002 colposcopy terminology was used. In the histopathologic analysis of colposcopic biopsies, Bethesda System 2014 version and also HPV ascia LAST in ano-genital lesion coexistence were used for classification. \u0000Findings: Patients were selected among 11,850 patients who applied to the hospital between 2015 and 2016 and were received cervical cytology specimens. 5180 patients were in menopausal period. 1102 of these patients have LSIL. 278 of the LSIL 1102 patients were reported as HPV (+) CIN I neoplasia and the remaining 824 patients as HPV (-) non-neoplastic lesion. CIN I lesion in 270 patients and CIN II lesion in 8 were determined with colposcopic biopsy performed in HPV-DNA (+) group (n=278). CIN I lesion in 670 patients and CIN II in 14 patients were also found with colposcopic biopsy performed in HPV-DNA (-) group (n=840); in 140 patients dysplasia was not observed. \u0000We think that only HPV-DNA analysis is not appropriate for menopausal HPV (+), pap smear negative patients with negative","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48841497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2324-9110-C2-010
Galina Migalko
{"title":"Is X-ray mammography accelerating the epidemic of breast cancer?","authors":"Galina Migalko","doi":"10.4172/2324-9110-C2-010","DOIUrl":"https://doi.org/10.4172/2324-9110-C2-010","url":null,"abstract":"","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70250250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2324-9110-C2-012
D. Šaponjski
{"title":"MDCT in estimation of an angle size of blood vessels invasion by pancreatic carcinoma","authors":"D. Šaponjski","doi":"10.4172/2324-9110-C2-012","DOIUrl":"https://doi.org/10.4172/2324-9110-C2-012","url":null,"abstract":"","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70250284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2324-9110-c1-007
Hiroshi Kobayashi
{"title":"Innovation of anti-cancer chemotherapy specific to acidic nests","authors":"Hiroshi Kobayashi","doi":"10.4172/2324-9110-c1-007","DOIUrl":"https://doi.org/10.4172/2324-9110-c1-007","url":null,"abstract":"","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70250137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2324-9110-C4-018
M. Tahmouresi
{"title":"Concordance of diffusion-weighted MRI and rectoscopy in the determination of rectal cancer location","authors":"M. Tahmouresi","doi":"10.4172/2324-9110-C4-018","DOIUrl":"https://doi.org/10.4172/2324-9110-C4-018","url":null,"abstract":"","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70250390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2324-9110.1000233
S. Kansal, Sanjay Jain, A. Yadav
Ewing’s sarcoma/primitive neuroectodermal tumor (ES/PNET) is an aggressive tumor derived from the neuroectoderm, commonly arising in the bone and soft tissues of the extremities [1,2]. ES/PNET arising in spermatic cord is extremely uncommon. We report a case study of this rare entity highlighting the characteristic histomorphological and immunohistochemical features.
{"title":"Ewing’s Sarcoma/Primitive Neuroectodermal Tumor of Spermatic Cord: A Rare Entity","authors":"S. Kansal, Sanjay Jain, A. Yadav","doi":"10.4172/2324-9110.1000233","DOIUrl":"https://doi.org/10.4172/2324-9110.1000233","url":null,"abstract":"Ewing’s sarcoma/primitive neuroectodermal tumor (ES/PNET) is an aggressive tumor derived from the neuroectoderm, commonly arising in the bone and soft tissues of the extremities [1,2]. ES/PNET arising in spermatic cord is extremely uncommon. We report a case study of this rare entity highlighting the characteristic histomorphological and immunohistochemical features.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70249643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：